# Eltrombopag for Moderate Aplastic Anemia

> **NCT01328587** · PHASE2 · COMPLETED · sponsor: **National Heart, Lung, and Blood Institute (NHLBI)** · enrollment: 34 (actual)

## Conditions studied

- Moderate Aplastic Anemia
- Unilineage Bone Marrow Failure Disorders

## Interventions

- **DRUG:** Eltrombopag

## Key facts

- **NCT ID:** NCT01328587
- **Lead sponsor:** National Heart, Lung, and Blood Institute (NHLBI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-03-13
- **Primary completion:** 2018-03-30
- **Final completion:** 2026-01-06
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2026-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01328587

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01328587, "Eltrombopag for Moderate Aplastic Anemia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01328587. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*